<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>THIOTHIXENE- thiothixene capsule </strong><br>Mylan Institutional Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_08d65730-515b-e341-50c6-8070ca69855f"></a><a name="section-1"></a><p></p>
<h1>WARNING</h1>
<p class="First"><span class="Bold">Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: </span>Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Thiothixene is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (see <a href="#i4i_warnings_id_24ceac24-8425-ee90-7769-e22a6521819d">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_5631e5b0-9e59-2151-ce4c-19f04cc93b86"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Thiothixene is a thioxanthene derivative. Specifically, it is the <span class="Italics">cis </span>isomer of <span class="Italics">N,N</span>-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide. It may be represented by the following structural formula:</p>
<div class="Figure">
<a name="id832"></a><img alt="Thiothixene Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92a1f215-e063-4c3e-89f5-f56d78a4c64e&amp;name=90981891-dd90-4163-84dd-45115511a549-01.jpg">
</div>
<p>The thioxanthenes differ from the phenothiazines by the replacement of nitrogen in the central ring with a carbon-linked side chain fixed in space in a rigid structural configuration. An N,N-dimethyl sulfonamide functional group is bonded to the thioxanthene nucleus.</p>
<p>Each capsule contains 1 mg, 2 mg, 5 mg or 10 mg of thiothixene, USP and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, powdered cellulose, pregelatinized starch and sodium lauryl sulfate. Each of the empty gelatin capsules contains FD&amp;C Blue No. 1, FD&amp;C Red No. 40, FD&amp;C Yellow No. 6, gelatin and titanium dioxide. In addition, the 1 mg empty gelatin capsules contain D&amp;C Red No. 28 and the 2 mg empty gelatin capsules contain D&amp;C Yellow No. 10.</p>
<p>The imprinting ink contains the following: black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, propylene glycol and shellac glaze.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_c4dcabfa-48f0-2f83-0db9-e81280463870"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Thiothixene is an antipsychotic of the thioxanthene series. Thiothixene possesses certain chemical and pharmacological similarities to the piperazine phenothiazines and differences from the aliphatic group of phenothiazines.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_e7ae1c55-72ed-e131-9c6f-ca6a78fa052e"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Thiothixene capsules are effective in the management of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Thiothixene capsules have not been evaluated in the management of behavioral complications in patients with <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_8e3cdbd8-5f33-e81b-47be-567d22b80627"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Thiothixene capsules are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> states, central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> due to any cause, and <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>. Thiothixene is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug. It is not known whether there is a cross sensitivity between the thioxanthenes and the phenothiazine derivatives, but this possibility should be considered.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_24ceac24-8425-ee90-7769-e22a6521819d"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d9a126ca-7be3-2f81-79da-9712126842e2"></a><a name="section-5.1"></a><p></p>
<h2>Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Thiothixene is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (see <a href="#id_08d65730-515b-e341-50c6-8070ca69855f">BOXED WARNING</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b247c95-3802-ec12-7913-8eecbade950a"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span>, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs, including thiothixene<span class="Sup">1</span>. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is unknown.</p>
<p>Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.</p>
<p>There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying disease process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p>
<p>Given these considerations, antipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that, 1) is known to respond to antipsychotic drugs, and 2) for whom alternative, equally effective, but potentially less harmful treatments are <span class="Italics">not</span> available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p>
<p>If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient on antipsychotics, drug discontinuation should be considered. However, some patients may require treatment despite the presence of the syndrome.</p>
<p>(For further information about the description of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and its clinical detection, please refer to <a href="#i4i_info_patients_id_24a85862-6cf4-4b34-8932-6a2a9a3549c3">Information for Patients in the PRECAUTIONS</a> section, and to the <a href="#i4i_adverse_effects_id_d5bb6b54-1717-6ba5-f615-9e440822bb62">ADVERSE REACTIONS</a> section.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20268ac1-8fe6-bd00-2c21-2705fb244bd7"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with antipsychotic drugs, including thiothixene<span class="Sup">2</span>. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS) pathology.</p>
<p>The management of NMS should include 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7f99403e-7f47-b367-a30f-cd506ce2b55d"></a><a name="section-5.4"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Safe use of thiothixene during pregnancy has not been established. Therefore, this drug should be given to pregnant patients only when, in the judgment of the physician, the expected benefits from the treatment exceed the possible risks to mother and fetus. Animal reproduction studies and clinical experience to date have not demonstrated any teratogenic effects.</p>
<p>In the animal reproduction studies with thiothixene, there was some decrease in conception rate and litter size, and an increase in resorption rate in rats and rabbits. Similar findings have been reported with other psychotropic agents. After repeated oral administration of thiothixene to rats (5 to 15 mg/kg/day), rabbits (3 to 50 mg/kg/day), and monkeys (1 to 3 mg/kg/day) before and during gestation, no teratogenic effects were seen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df08ffad-c2aa-fdf5-259d-8e2a3fdd977d"></a><a name="section-5.5"></a><p></p>
<h2>Usage in Children</h2>
<p class="First">The use of thiothixene in children under 12 years of age is not recommended because safe conditions for its use have not been established.</p>
<p>As is true with many CNS drugs, thiothixene may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery, especially during the first few days of therapy. Therefore, the patient should be cautioned accordingly.</p>
<p>As in the case of other CNS-acting drugs, patients receiving thiothixene should be cautioned about the possible additive effects (which may include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) with CNS depressants and with alcohol.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_fa0067c4-c370-be06-ed53-c6a809db8d30"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">An antiemetic effect was observed in animal studies with thiothixene; since this effect may also occur in man, it is possible that thiothixene may mask signs of overdosage of toxic drugs and may obscure conditions such as <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span> and <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span>.</p>
<p>In consideration of the known capability of thiothixene and certain other psychotropic drugs to precipitate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, extreme caution should be used in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span> or those in a state of alcohol withdrawal, since it may lower the convulsive threshold. Although thiothixene potentiates the actions of the barbiturates, the dosage of the anticonvulsant therapy should not be reduced when thiothixene is administered concurrently.</p>
<p>Though exhibiting rather weak anticholinergic properties, thiothixene should be used with caution in patients who might be exposed to extreme heat or who are receiving atropine or related drugs.</p>
<p>Use with caution in patients with cardiovascular disease.</p>
<p>Caution as well as careful adjustment of the dosages is indicated when thiothixene is used in conjunction with other CNS depressants.</p>
<p>Also, careful observation should be made for pigmentary <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> and lenticular <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> (fine lenticular <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> has been noted in a small number of patients treated with thiothixene for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>). <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span> (<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>), and <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">biliary stasis</span>), have been reported with related drugs.</p>
<p>Antipsychotic drugs, including thiothixene<span class="Sup">3</span>, elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f786e85c-9ff4-4316-a245-eafbb69093a5"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e64f438a-fe6c-453b-b6cc-7d3c42aef392"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Class Effect</span></h3>
<p class="First">In clinical trial and/or post-marketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported temporally related to antipsychotic agents. </p>
<p> Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include preexisting low white blood cell count (WBC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Patients with a history of a clinically significant low WBC or drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of thiothixene should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. </p>
<p> Patients with clinically significant <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms or signs occur. Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt; 1000/mm<span class="Sup">3</span>) should discontinue thiothixene and have their WBC followed until recovery. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_24a85862-6cf4-4b34-8932-6a2a9a3549c3"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Given the likelihood that some patients exposed chronically to antipsychotics will develop <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_81759471-f170-4966-a748-871c532463fa"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. Patients receiving these drugs should be observed for signs of reduced thiothixene effectiveness<span class="Sup">4,5</span>.</p>
<p>Due to a possible additive effect with hypotensive agents, patients receiving these drugs should be observed closely for signs of excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> when thiothixene is added to their drug regimen<span class="Sup">6</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d5bb6b54-1717-6ba5-f615-9e440822bb62"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">NOTE: </span>Not all of the following adverse reactions have been reported with thiothixene. However, since thiothixene has certain chemical and pharmacologic similarities to the phenothiazines, all of the known side effects and toxicity associated with phenothiazine therapy should be borne in mind when thiothixene is used.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_69fc204c-5487-c2c0-6709-c34e4e2eefb0"></a><a name="section-7.1"></a><p></p>
<h2>Cardiovascular Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, light-headedness, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. In the event <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, epinephrine should not be used as a pressor agent since a paradoxical further lowering of blood pressure may result. Nonspecific EKG changes have been observed in some patients receiving thiothixene. These changes are usually reversible and frequently disappear on continued thiothixene therapy. The incidence of these changes is lower than that observed with some phenothiazines. The clinical significance of these changes is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d54cb77-0fc1-9e22-8ec6-3b1ee76eebba"></a><a name="section-7.2"></a><p></p>
<h2>CNS Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, usually mild, may occur although it usually subsides with continuation of thiothixene therapy. The incidence of sedation appears similar to that of the piperazine group of phenothiazines but less than that of certain aliphatic phenothiazines. <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> have been noted with thiothixene. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> and paradoxical exacerbation of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms have occurred with thiothixene infrequently.</p>
<p><span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">Hyperreflexia</span> has been reported in infants delivered from mothers having received structurally related drugs.</p>
<p>In addition, phenothiazine derivatives have been associated with <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> and cerebrospinal fluid abnormalities.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a9841241-e3b6-2778-4740-a6538cc60dc4"></a><a name="section-7.2.1"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span>, such as <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">pseudoparkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> and <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> have been reported (see <a href="#i4i_section_id_9b54884a-6230-932a-d279-30883fb20af4">Adverse Reactions: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>: Class Effect</a>). Management of these <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> depends upon the type and severity. Rapid relief of acute symptoms may require the use of an injectable antiparkinson agent. More slowly emerging symptoms may be managed by reducing the dosage of thiothixene and/or administering an oral antiparkinson agent.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_03e0bf9b-cf22-9776-7511-9939e30c22f7"></a><a name="section-7.2.1.1"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></span></h4>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b54884a-6230-932a-d279-30883fb20af4"></a><a name="section-7.2.1.1.1"></a><p></p>
<h5>Class Effect</h5>
<p class="First">Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8e8228f-5164-7ce8-d2d4-9ea36fd6424b"></a><a name="section-7.2.2"></a><p></p>
<h3><span class="Bold">Persistent <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></span></h3>
<p class="First">As with all antipsychotic agents, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> may appear in some patients on long-term therapy with thiothixene, or may occur after drug therapy has been discontinued. The syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of extremities.</p>
<p>Since early detection of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is important, patients should be monitored on an ongoing basis. It has been reported that fine vermicular movement of the tongue may be an early sign of the syndrome. If this or any other presentation of the syndrome is observed, the clinician should consider possible discontinuation of antipsychotic medication. (See <a href="#i4i_warnings_id_24ceac24-8425-ee90-7769-e22a6521819d">WARNINGS</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3ea53420-da22-721e-41e0-9c418c35b43f"></a><a name="section-7.3"></a><p></p>
<h2>Hepatic Effects</h2>
<p class="First">Elevations of serum transaminase and alkaline phosphatase, usually transient, have been infrequently observed in some patients. No clinically confirmed cases of <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> attributable to thiothixene have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56683a7c-130b-ef96-9f90-dbe4a044b644"></a><a name="section-7.4"></a><p></p>
<h2>Hematologic Effects</h2>
<p class="First">As is true with certain other psychotropic drugs, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and leucocytosis, which are usually transient, can occur occasionally with thiothixene. Other antipsychotic drugs have been associated with <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5acb778e-49d1-0c73-7a10-3bb5f2c70368"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported with thiothixene. Undue exposure to sunlight should be avoided. Although not experienced with thiothixene, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> (in nursing personnel) have been reported with certain phenothiazines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d599d799-939d-a9fc-bccc-5b036c9c5be6"></a><a name="section-7.6"></a><p></p>
<h2>Endocrine/Reproductive</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span><span class="Sup">3</span>,  lactation, menstrual irregularities, moderate <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span> and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> have occurred in a small percentage of females receiving thiothixene. If persistent, this may necessitate a reduction in dosage or the discontinuation of therapy. Phenothiazines have been associated with false <span class="product-label-link" type="condition" conceptid="4094910" conceptname="Pregnancy test positive">positive pregnancy tests</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c6448df7-000e-5515-1b12-c8200b8c735c"></a><a name="section-7.7"></a><p></p>
<h2>Autonomic Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span> and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have occurred infrequently with thiothixene therapy. Phenothiazines have been associated with <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, and <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">adynamic ileus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a0583a7f-4d85-4536-eb0f-3552cfb82295"></a><a name="section-7.8"></a><p></p>
<h2>Other Adverse Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, increase in appetite and weight, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.</p>
<p>Although not reported with thiothixene, evidence indicates there is a relationship between phenothiazine therapy and the occurrence of a <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>-like syndrome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39ee9a3f-ce00-3f2d-6ff8-47615862f223"></a><a name="section-7.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</h2>
<p class="First">Please refer to the text regarding NMS in the <a href="#i4i_warnings_id_24ceac24-8425-ee90-7769-e22a6521819d">WARNINGS</a> section.</p>
<p><span class="Bold">NOTE:</span> <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden deaths</span> have occasionally been reported in patients who have received certain phenothiazine derivatives. In some cases the cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was apparently <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="4139960" conceptname="Strangulation">asphyxia</span> due to failure of the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex. In others, the cause could not be determined nor could it be established that <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was due to phenothiazine administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_28f59624-bb73-6d76-eb40-7f7543607784"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Manifestations include muscular <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Symptoms of gross overdosage may include <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, disturbances of gait, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c019e634-f26e-871f-3aa0-79d5d83984f1"></a><a name="section-8.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Essentially symptomatic and supportive. Early gastric lavage is helpful. Keep patient under careful observation and maintain an open airway, since involvement of the extrapyramidal system may produce <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> and respiratory difficulty in severe overdosage. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the standard measures for managing circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> should be used (I.V. fluids and/or vasoconstrictors).</p>
<p>If a vasoconstrictor is needed, norepinephrine and phenylephrine are the most suitable drugs. Other pressor agents, including epinephrine, are not recommended, since phenothiazine derivatives may reverse the usual pressor action of these agents and cause further lowering of blood pressure.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> is marked, symptomatic treatment is indicated. <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> may be treated with antiparkinson drugs.</p>
<p>There are no data on the use of peritoneal or hemodialysis, but they are known to be of little value in phenothiazine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d6a4efb8-4a2d-52ff-e985-9ab2301bb726"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage of thiothixene capsules should be individually adjusted depending on the chronicity and severity of the symptoms of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. In general, small doses should be used initially and gradually increased to the optimal effective level, based on patient response.</p>
<p>Some patients have been successfully maintained on once a day thiothixene capsule therapy.</p>
<p>The use of thiothixene capsules in children under 12 years of age is not recommended because safe conditions for its use have not been established.</p>
<p>In milder conditions, an initial dose of 2 mg three times daily is recommended. If indicated, a subsequent increase to 15 mg/day total daily dose is often effective.</p>
<p>In more severe conditions, an initial dose of 5 mg twice daily is recommended.</p>
<p>The usual optimal dose is 20 mg to 30 mg daily. If indicated, an increase to 60 mg/day total daily dose is often effective. Exceeding a total daily dose of 60 mg rarely increases the beneficial response.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_c478ae68-ae1e-9811-d208-e3014190df7f"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Thiothixene Capsules, USP are available containing 2 mg, 5 mg or 10 mg of thiothixene, USP.</p>
<p>The 2 mg capsule is a hard-shell gelatin capsule with a caramel opaque cap and a yellow opaque body filled with white to off-white powder. The capsule is axially imprinted with <span class="Bold">MYLAN </span>over<span class="Bold"> 2002</span> in black ink on both the cap and body. They are available as follows:</p>
<p>NDC 51079-587-20 – Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 100 (10 cards of 10 capsules each).</p>
<p>The 5 mg capsule is a hard-shell gelatin capsule with a caramel opaque cap and a white opaque body filled with white to off-white powder. The capsule is axially imprinted with <span class="Bold">MYLAN </span>over<span class="Bold"> 3005</span> in black ink on both the cap and body. They are available as follows:</p>
<p>NDC 51079-588-20 – Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 100 (10 cards of 10 capsules each).</p>
<p>The 10 mg capsule is a hard-shell gelatin capsule with a caramel opaque cap and a peach opaque body filled with white to off-white powder. The capsule is axially imprinted with <span class="Bold">MYLAN </span>over<span class="Bold"> 5010</span> in black ink on both the cap and body. They are available as follows:</p>
<p>NDC 51079-589-20 – Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 100 (10 cards of 10 capsules each).</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span><br><span class="Bold">Protect from light.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_a9c25969-3bef-42b8-b804-e2fe7c3c5082"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>•</dt>
<dd>Worldwide Labeling Safety Report: <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span> and <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Dyskinesia Tardive</span> and Thiothixene, (16Apr02). </dd>
<dt>•</dt>
<dd>Worldwide Labeling Safety Report: <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> and Thiothixene, (16Apr02). </dd>
<dt>•</dt>
<dd>Worldwide Labeling Safety Report: <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> and Thiothixene, (16Apr02). </dd>
<dt>•</dt>
<dd>Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic Interactions</span>: A Study of Hepatic Enzyme Inducers, Clearance Inhibitors, and Demographic Variables. <span class="Italics">Journal of Clinical Psychopharmacology, </span>11(5):296–301, (1991). </dd>
<dt>•</dt>
<dd>Worldwide Labeling Safety Report: Drug Interaction and Thiothixene, (09May02). </dd>
<dt>•</dt>
<dd>McEvoy GK, Miller JL, Snow EK, et al. AHFS Drug Information. American Society of Health-System Pharmacists, Inc., p. 2334-2336, (2002). </dd>
<dt>•</dt>
<dd>Worldwide Labeling Safety Report: <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">Menstrual Disorder</span> and Thiothixene, (16Apr02). </dd>
</dl>
<p class="First">Manufactured by:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Distributed by:<br><span class="Bold">Mylan Institutional Inc.</span><br>Rockford, IL 61103 U.S.A.</p>
<p>S-4422 R14<br>10/12</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ca0ebd5b-8b92-431d-8a4a-b3cd5b593e0b"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 2 mg</span></p>
<p>NDC 51079-587-20</p>
<p><span class="Bold">Thiothixene</span><br><span class="Bold">Capsules, USP</span><br><span class="Bold">2 mg</span></p>
<p>100 Capsules (10 x 10)</p>
<p>Each capsule contains:<br>Thiothixene, USP  <span class="Bold">.  .  .  .</span>  2 mg</p>
<p><span class="Bold">Dosage </span>- In mild conditions:<br>6 mg to 15 mg daily. In severe<br>conditions: 10 mg to 60 mg daily.</p>
<p><span class="Bold">Usual Optimal Dosage: </span>20 mg to<br>30 mg daily. See insert.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><span class="Bold">Temperature.]</span><br><span class="Bold">Protect from light.</span></p>
<p>Manufactured by:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Packaged and Distributed by:</p>
<p><span class="Bold">Mylan Institutional Inc.</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>This unit dose package is not child resistant.</p>
<p>For institutional use only.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<p>This container provides light-resistance.</p>
<p>See window for lot number and expiration date.</p>
<p><span class="Bold">Rx only</span></p>
<p>S-4424 R8</p>
<div class="Figure">
<a name="id-706182459"></a><img alt="Thiothixene 2 mg Capsules Unit Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92a1f215-e063-4c3e-89f5-f56d78a4c64e&amp;name=image-01.jpg">
</div>
<div class="Figure">
<a name="id-1207872473"></a><img alt="Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92a1f215-e063-4c3e-89f5-f56d78a4c64e&amp;name=image-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_7c400c44-de24-4da2-b3a8-6944c6e461c6"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg</span></p>
<p>NDC 51079-588-20</p>
<p><span class="Bold">Thiothixene</span><br><span class="Bold">Capsules, USP</span><br><span class="Bold">5 mg</span></p>
<p>100 Capsules (10 x 10)</p>
<p>Each capsule contains:<br>Thiothixene, USP<span class="Bold">  .  .  .  .  </span>5 mg</p>
<p><span class="Bold">Dosage </span>- In mild conditions:<br>6 mg to 15 mg daily. In severe<br>conditions: 10 mg to 60 mg daily.</p>
<p><span class="Bold">Usual Optimal Dosage: </span>20 mg to<br>30 mg daily. See insert.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room Temperature.]</span><br><span class="Bold">Protect from light.</span></p>
<p>Manufactured by:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Rx only</span></p>
<p>S-4425 R7</p>
<p>Packaged and Distributed by:</p>
<p><span class="Bold">Mylan Institutional Inc.</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>This unit dose package is not child resistant.</p>
<p>For institutional use only.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<p>This container provides light-resistance.</p>
<p>See window for lot number and expiration date.</p>
<div class="Figure">
<a name="id-457190063"></a><img alt="Thiothixene 5 mg Capsules Unit Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92a1f215-e063-4c3e-89f5-f56d78a4c64e&amp;name=image-03.jpg">
</div>
<div class="Figure">
<a name="id1682471870"></a><img alt="Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92a1f215-e063-4c3e-89f5-f56d78a4c64e&amp;name=image-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_241afaf0-879d-4087-8630-91b41b2e3f26"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg</span></p>
<p>NDC 51079-589-20</p>
<p><span class="Bold">Thiothixene</span><br><span class="Bold">Capsules, USP</span><br><span class="Bold">10 mg</span></p>
<p>100 Capsules (10 x 10)</p>
<p>Each capsule contains:<br>Thiothixene, USP  <span class="Bold">.  .  .  .</span>  10 mg</p>
<p><span class="Bold">Dosage </span>- In mild conditions:<br>6 mg to 15 mg daily. In severe<br>conditions: 10 mg to 60 mg daily.</p>
<p><span class="Bold">Usual Optimal Dosage: </span>20 mg to<br>30 mg daily. See insert.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room Temperature.]</span><br><span class="Bold">Protect from light.</span></p>
<p>Manufactured by:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Packaged and Distributed by:</p>
<p><span class="Bold">Mylan Institutional Inc.</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>This unit dose package is not child resistant.</p>
<p>For institutional use only.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<p>This container provides light-resistance.</p>
<p>See window for lot number and expiration date.</p>
<p><span class="Bold">Rx only</span></p>
<p>S-4426 R6</p>
<div class="Figure">
<a name="id1572000770"></a><img alt="Thiothixene 10 mg Capsules Unit Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92a1f215-e063-4c3e-89f5-f56d78a4c64e&amp;name=image-05.jpg">
</div>
<div class="Figure">
<a name="id1804504028"></a><img alt="Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92a1f215-e063-4c3e-89f5-f56d78a4c64e&amp;name=image-06.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>THIOTHIXENE 		
					</strong><br><span class="contentTableReg">thiothixene capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51079-587(NDC:0378-2002)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>THIOTHIXENE</strong> (THIOTHIXENE) </td>
<td class="formItem">THIOTHIXENE</td>
<td class="formItem">2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (caramel opaque) , YELLOW (yellow opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;2002</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-587-20</td>
<td class="formItem">100  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-587-01</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071093</td>
<td class="formItem">03/09/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>THIOTHIXENE 		
					</strong><br><span class="contentTableReg">thiothixene capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51079-588(NDC:0378-3005)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>THIOTHIXENE</strong> (THIOTHIXENE) </td>
<td class="formItem">THIOTHIXENE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (caramel opaque) , WHITE (white opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;3005</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-588-20</td>
<td class="formItem">100  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-588-01</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071093</td>
<td class="formItem">03/05/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>THIOTHIXENE 		
					</strong><br><span class="contentTableReg">thiothixene capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51079-589(NDC:0378-5010)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>THIOTHIXENE</strong> (THIOTHIXENE) </td>
<td class="formItem">THIOTHIXENE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (caramel opaque) , ORANGE (peach opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;5010</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-589-20</td>
<td class="formItem">100  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-589-01</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071093</td>
<td class="formItem">07/24/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional Inc.
							(039615992)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b5aebe5d-f6c7-4e47-8623-e1f949472cbe</div>
<div>Set id: 92a1f215-e063-4c3e-89f5-f56d78a4c64e</div>
<div>Version: 3</div>
<div>Effective Time: 20121005</div>
</div>
</div> <div class="DistributorName">Mylan Institutional Inc.</div></p>
</body></html>
